Matches in Wikidata for { <http://www.wikidata.org/entity/Q64636567> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- Q64636567 description "clinical trial" @default.
- Q64636567 description "ensayu clínicu" @default.
- Q64636567 description "klinisch onderzoek" @default.
- Q64636567 description "клінічне випробування" @default.
- Q64636567 name "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)" @default.
- Q64636567 type Item @default.
- Q64636567 label "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)" @default.
- Q64636567 prefLabel "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)" @default.
- Q64636567 P1132 Q64636567-25704C79-82D1-436B-B393-590E865B6D8C @default.
- Q64636567 P1476 Q64636567-F577DAD7-1734-480A-B33B-275AC35248D9 @default.
- Q64636567 P17 Q64636567-14B20207-A729-412B-85B1-97B09F3218EC @default.
- Q64636567 P17 Q64636567-19FDBBB9-408E-4876-B567-DEA2DD0F3786 @default.
- Q64636567 P17 Q64636567-1F95D876-083D-4FDC-834B-AAA65661FA21 @default.
- Q64636567 P17 Q64636567-2CCDEBB3-C174-4D23-8A51-5153273AEC88 @default.
- Q64636567 P17 Q64636567-39751FBB-BDFF-478D-81EC-25A1DF729B56 @default.
- Q64636567 P17 Q64636567-3FD4AF87-DECE-4A39-BB50-F2CD4AC54297 @default.
- Q64636567 P17 Q64636567-5490635B-508B-4CF0-B7D6-161A1F8649F2 @default.
- Q64636567 P17 Q64636567-753F5E16-FDC9-4A97-A874-06B6A2D74A7C @default.
- Q64636567 P17 Q64636567-AAF81B34-9744-4A2A-8298-A5FDDC336BC6 @default.
- Q64636567 P17 Q64636567-DD8E3C7A-5176-4852-8E2C-81772EDC59E2 @default.
- Q64636567 P17 Q64636567-F3C4B26B-E78C-4427-9C9B-114C3EB4201A @default.
- Q64636567 P1813 Q64636567-CEF77642-A5B0-4E73-AA32-87747E0F29DB @default.
- Q64636567 P2899 Q64636567-EAA73B1C-AC66-4064-8B7D-7CE6803A1162 @default.
- Q64636567 P3098 Q64636567-56EB88B7-8651-4D28-8878-D9CF4B3491F4 @default.
- Q64636567 P31 Q64636567-E4E8A664-E854-4DDD-AF0F-99B7379DEB15 @default.
- Q64636567 P4135 Q64636567-8DDD0BFD-0CC7-400E-8726-00542C9E7563 @default.
- Q64636567 P580 Q64636567-8EEAC896-0B7D-412F-8B01-2E04A3249402 @default.
- Q64636567 P582 Q64636567-20B50A8A-EA28-4CE1-9DD7-DA224DEE0ADA @default.
- Q64636567 P6099 Q64636567-28842572-58FC-4112-9991-F45D5F56C600 @default.
- Q64636567 P6153 Q64636567-2B91CC0F-6166-473A-9D93-E2061DC8B665 @default.
- Q64636567 P6153 Q64636567-2CAE702B-C6B1-4AA8-865A-86637DCEDC07 @default.
- Q64636567 P6153 Q64636567-309A6CC1-713F-4E79-BAA3-421856199537 @default.
- Q64636567 P6153 Q64636567-3562106D-FA98-450E-ADD8-90D713159359 @default.
- Q64636567 P6153 Q64636567-3F3D0AFF-DB80-4F08-A68D-ADEC3BDC465D @default.
- Q64636567 P6153 Q64636567-5C8994FD-7E8C-41D1-B9EA-6A5B58734F0C @default.
- Q64636567 P6153 Q64636567-5E4CCF24-CBEF-4C8E-81F5-107514703C00 @default.
- Q64636567 P6153 Q64636567-5F220F88-7EF8-4162-A21A-D4E2C465712B @default.
- Q64636567 P6153 Q64636567-5F48A2CD-2B28-416D-95E1-6EC3D6741B30 @default.
- Q64636567 P6153 Q64636567-70F4A17B-D1FF-4F2A-A059-DC1BDFAC39AE @default.
- Q64636567 P6153 Q64636567-86355022-1AD1-4607-B593-7B61F3C92072 @default.
- Q64636567 P6153 Q64636567-8E8DA387-475C-4C7F-8ECE-B52ADFA1C06F @default.
- Q64636567 P6153 Q64636567-C56A69F7-41D9-4F2F-A43F-F2DC802A4965 @default.
- Q64636567 P6153 Q64636567-C64F0700-E7D0-4596-9D11-D2F249E9C82D @default.
- Q64636567 P6153 Q64636567-DE37A991-FF76-4CDF-AF30-BC5AEFDDFF9A @default.
- Q64636567 P6153 Q64636567-E33EAA1F-1606-4D86-93A5-36EA2C8B76E1 @default.
- Q64636567 P6153 Q64636567-F14AFF34-CD23-4654-A9E1-3ED2617C40B3 @default.
- Q64636567 P6153 Q64636567-F4EF79B0-3461-47D7-8B6C-F1E30AB1CC06 @default.
- Q64636567 P8363 Q64636567-21585C00-FF58-490B-924F-DDEF58375492 @default.
- Q64636567 P1132 "+388" @default.
- Q64636567 P1476 "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis" @default.
- Q64636567 P17 Q155 @default.
- Q64636567 P17 Q29 @default.
- Q64636567 P17 Q30 @default.
- Q64636567 P17 Q31 @default.
- Q64636567 P17 Q43 @default.
- Q64636567 P17 Q766 @default.
- Q64636567 P17 Q786 @default.
- Q64636567 P17 Q804 @default.
- Q64636567 P17 Q810 @default.
- Q64636567 P17 Q822 @default.
- Q64636567 P17 Q842 @default.
- Q64636567 P1813 "EPIC" @default.
- Q64636567 P2899 "+4" @default.
- Q64636567 P3098 "NCT01737814" @default.
- Q64636567 P31 Q30612 @default.
- Q64636567 P4135 "+65" @default.
- Q64636567 P580 "2013-05-01T00:00:00Z" @default.
- Q64636567 P582 "2016-02-01T00:00:00Z" @default.
- Q64636567 P6099 Q42824827 @default.
- Q64636567 P6153 Q1047060 @default.
- Q64636567 P6153 Q1068752 @default.
- Q64636567 P6153 Q1277776 @default.
- Q64636567 P6153 Q13572981 @default.
- Q64636567 P6153 Q1433199 @default.
- Q64636567 P6153 Q18156816 @default.
- Q64636567 P6153 Q30279912 @default.
- Q64636567 P6153 Q30287248 @default.
- Q64636567 P6153 Q309350 @default.
- Q64636567 P6153 Q4569202 @default.
- Q64636567 P6153 Q5098130 @default.
- Q64636567 P6153 Q5098131 @default.
- Q64636567 P6153 Q5120231 @default.
- Q64636567 P6153 Q5547686 @default.
- Q64636567 P6153 Q5592136 @default.
- Q64636567 P6153 Q738258 @default.
- Q64636567 P6153 Q7681712 @default.
- Q64636567 P6153 Q7895818 @default.
- Q64636567 P8363 Q78089383 @default.